MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-04-2026
Bio-Techne Corporation Interest Expense 2011-2026 | TECH
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Bio-Techne Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 831 K | -8.58 M | 47.5 M | 15.3 M | 14 M | 19.2 M | 21.7 M | 10.2 M | 7.36 M | 1.75 M | 1.54 M | - | - | -3.4 M | -1.83 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.5 M | -8.58 M | 9.66 M |
Quarterly Interest Expense Bio-Techne Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 4 M | 4.33 M | 4.89 M | - | 1.37 M | 2.36 M | 3.79 M | 6.15 M | 2.49 M | 2.9 M | 3.41 M | 6.31 M | 2.66 M | 3.58 M | 4.42 M | 3.58 M | 4.42 M | 4.87 M | 5.22 M | 4.87 M | 5.22 M | 5.76 M | 5.24 M | 5.76 M | 5.24 M | 2.33 M | 2.24 M | 2.33 M | 2.24 M | 1.92 M | 1.4 M | 1.84 M | 1.34 M | 400 K | 451 K | 400 K | 451 K | 437 K | 311 K | 437 K | 311 K | - | - | -71 K | -304 K | -135 K | -478 K | -135 K | -478 K | -607 K | -1.18 M | -607 K | -1.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.31 M | -1.18 M | 2.33 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
14.2 M | $ 97.54 | -5.71 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |
 |
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | USA |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Cerus Corporation
CERS
|
3.02 M | $ 2.72 | 33.99 % | $ 518 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
1.82 M | $ 21.95 | -2.23 % | $ 3.64 B | USA |
 |
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | USA |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
2.65 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | USA |
 |
Cardiff Oncology
CRDF
|
5 K | $ 1.71 | -1.16 % | $ 114 M | USA |
 |
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | USA |
 |
Editas Medicine
EDIT
|
-2.19 M | $ 2.9 | -3.33 % | $ 257 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
293 K | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 2.93 | -8.15 % | $ 4.82 M |  Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
5.47 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-1.65 M | - | -5.68 % | $ 8.28 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | USA |